At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- CMR and CTCA with CT-FFR (diagnostic test)
- How long the study runs
- Study runs about 60 months (dates as stated)
- About the drug or intervention
- CMR and CTCA with CT-FFR — diagnostic test: multi-parametric CMR assessment and CT coronary angiography with FFR assessment
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 300
- Started
- 2020-11-05
- Last checked
- 2025-06
Plain English Summary
What is this study?
- • Testing a new treatment for coronary artery disease
- • Clinical study - 300 participants
- • CONCORD is a prospective observational study evaluating the diagnostic accuracy of cardiovascular magnetic resonance (CMR) and computed tomography with fractional flow reserve (CT-FFR) in patients with suspected coronary artery disease, using invasive fractional flow reserve (FFR) as the reference standard
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with coronary artery disease
Where?
- • Leicester - Glenfield Hospital
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
CONCORD is a prospective observational study evaluating the diagnostic accuracy of cardiovascular magnetic resonance (CMR) and computed tomography with fractional flow reserve (CT-FFR) in patients with suspected coronary artery disease, using invasive fractional flow reserve (FFR) as the reference standard.
More detail
In patients with suspected coronary artery disease (CAD), CT coronary angiography (CTCA) provides excellent sensitivity and negative predictive value, enabling the safe exclusion of significant CAD. However, its positive predictive value remains suboptimal (c.50%). Undertaking additional CT-FFR improves specificity and positive predictive value, reducing unnecessary invasive coronary angiography. It has been established that CMR perfusion imaging offers excellent diagnostic accuracy for the identification of functionally significant coronary artery disease. The diagnostic performance of qualitative CMR perfusion assessment may be further enhanced by additional quantitative assessment. The purpose of this prospective observational study is to evaluate the diagnostic performance of all three modalities (CT-FFR and qualitative and quantitative CMR perfusion imaging), involving 300 patients with suspected coronary artery disease referred for invasive coronary angiography. A subset of 167 subjects will undergo an additional accelerated CMR scan for comparison. Invasively measured fractional flow reserve (FFR) will serve as the reference standard.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Patients aged ≥18 years
- ✓Referred for invasive coronary angiography for investigation of chest pain
Who cannot take part
- ✗Recent acute coronary syndrome (\< 6 months)
- ✗Previous coronary artery bypass grafting
- ✗Severe claustrophobia
- ✗Absolute contraindications to CMR - those with MR conditional or safe devices will be included
- ✗Second-/third-degree atrioventricular block
See the full criteria
Where Is This Study? (1 UK site)
Glenfield Hospital
Leicester LE3 (QP, United Kingdom
How to Get in Touch
Jayanth Arnold
Sponsor contactCONTACT
Mo Elshibly
Sponsor contactCONTACT